Pivotal Study of OCS-01 Eye Drops in Subjects with Diabetic Macular Edema (DIAMOND-2)

Last updated: October 31, 2024
Sponsor: Oculis
Overall Status: Active - Recruiting

Phase

3

Condition

Diabetic Retinopathy

Macular Edema

Diabetic Macular Edema

Treatment

Dexamethasone ophthalmic suspension (OCS-01)

Vehicle

Clinical Study ID

NCT06172257
DX221
  • Ages 18-85
  • All Genders

Study Summary

The primary objective is to evaluate the efficacy and safety of OCS 01 as compared to Vehicle in subjects with Diabetic Macular Edema (DME).

Eligibility Criteria

Inclusion

Inclusion Criteria (selection):

  1. Have a signed informed consent form before any study-specific procedures are performed.

  2. Have DME with presence of intraretinal and/or subretinal fluid in the study eye, with CST of ≥310 µm by SD-OCT at screening (Visit 1) (as assessed by an independent reading center).

  3. Have a documented diagnosis of Type 1 or Type 2 diabetes mellitus prior to screening (Visit 1).

Exclusion Criteria (selection):

  1. Have macular edema considered to be because of a cause other than DME.

  2. Have a decrease in BCVA because of causes other than DME.

  3. Have a known history of significant macular ischemia which would prevent gain in visual acuity in the study eye.

Study Design

Total Participants: 350
Treatment Group(s): 2
Primary Treatment: Dexamethasone ophthalmic suspension (OCS-01)
Phase: 3
Study Start date:
March 15, 2024
Estimated Completion Date:
June 30, 2026

Study Description

A Phase 3 Pivotal Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS 01 Eye Drops in Subjects with Diabetic Macular Edema

Connect with a study center

  • Oculis Investigative Site - Stanford Byers Eye Institute

    Palo Alto, California 94303
    United States

    Active - Recruiting

  • Oculis Investigative Site - Sierra Eye Associates

    Reno, Nevada 89502
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.